Skip to content
  • Home
  • Media
  • News
  • 2024 LEO Pharma announces changes to its Global Leadership Team

LEO Pharma announces changes to its Global Leadership Team

LEO Pharma today announced that Nathalie Daste, Executive Vice President of Global People & Corporate Affairs, has decided to resign her position and leave LEO Pharma due to personal reasons.

Christophe Bourdon, CEO of LEO Pharma, said: “I want to express heartfelt gratitude to Nathalie for her dedication to the journey we are currently on. In the Global Leadership Team, we will miss Nathalie, her engagement, and her fresh ideas, but I fully understand the need to put family first.


Nathalie Daste said: “It is with mixed emotions that I share the news of my departure from this remarkable organization. Due to unforeseen family circumstances, I have made the difficult decision to step away from my role. While it is hard to bid farewell to such a talented and dedicated team, I am confident that the organization will continue to thrive and achieve great things.


Effective immediately, Michael Meyer, currently Head of HR Business Partnering and an experienced HR leader, will step in until a permanent solution has been identified. As a result, he will also join the Global Leadership Team. Michael is recognized for his strong leadership and solid HR background from various roles and industries, with the last 12 years spent within LEO Pharma. Throughout his career, Michael has worked internationally across the entire pharma value chain and held leadership roles in Europe, North America, and Asia.


Following this change, LEO Pharma's Global Leadership Team will comprise the following executives: Christophe Bourdon, CEO, Philip Eickhoff, CFO, Sven Hauptmann, EVP, Technical Development and Supply, Brian Hilberdink, EVP, Region North America, Kreesten Meldgaard Madsen, CDO, Global Development, Michael Meyer, EVP, Global People & Corporate Affairs, Becki Morison, EVP, Global Product Strategy & International Operations, and Jacob Pontoppidan Thyssen, CSO, Research & Early Development.

About LEO Pharma

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,200 people, serving millions of patients across the world. In 2023, the company generated net sales of DKK 11.4 billion

Jeppe Ilkjaer

Jeppe Ilkjaer

Tel: +45 30502014